No Obvious Prescription For Biopharma Investors
This article was originally published in Start Up
Executive Summary
In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.
You may also be interested in...
Watchdog And Innovator: Modernizing The FDA-Industry Relationship
As each medical advance introduces a new regulatory challenge, FDA’s need for reinvention is as constant as industry’s need for innovation. If the agency is going to help sponsors bring breakthrough medicines to market, it must rethink its role as both watchdog and regulatory innovator.
NeXeption, Not The Rule: Another Twist On Asset-Based Financing
As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?
Venture Capital Survey Paints Bleak Portrait
A poll of 100 life science VCs reveals fears of industry contraction, increased importance of corporate investors, and attitudes on regulators, therapeutic areas and new investment models.